Tislelizumab-related enteritis successfully treated with adalimumab: A case report.
World J Clin Cases
; 10(28): 10186-10192, 2022 Oct 06.
Article
en En
| MEDLINE
| ID: mdl-36246838
ABSTRACT
BACKGROUND:
With programmed death-1 (PD-1) inhibitors becoming the standard treatment for lung cancer, PD-1-related adverse reactions and treatment have gradually become prominent. CASESUMMARY:
First reported case of tislelizumab-related enteritis successfully treated with adalimumab 40mg every 2 wk for 3 times in an advanced lung cancer patient who received first-line tislelizumab/pemetrexed/carboplatin for 4 cycles. The patient continued receiving the treatment of pemetrexed/carboplatin after symptoms, abdominal computed tomography and colonoscopy improved, significant diarrhea was not occurred.CONCLUSION:
Adalimumab can be an effective treatment option for patients with PD-1 antibody related enteritis if they do not respond well to glucocorticoid treatment.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
World J Clin Cases
Año:
2022
Tipo del documento:
Article
País de afiliación:
China